

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

MES-OV

RRID:CVCL_CZ92

Type: Cell Line

Proper Citation

ATCC Cat# CRL-3272, RRID:CVCL_CZ92

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_CZ92

Proper Citation: ATCC Cat# CRL-3272, RRID:CVCL_CZ92

Description: Cell line MES-OV is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian serous cystadenocarcinoma

Defining Citation: [PMID:12960427](#), [PMID:16382445](#)

Comments: Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MES-OV

Synonyms: MESOV

Cross References: ATCC:CRL-3272, cancercelllines:CVCL_CZ92, DepMap:ACH-002486, GEO:GSM95445, Progenetix:CVCL_CZ92, Wikidata:Q54905245

ID: CVCL_CZ92

Vendor: ATCC

Catalog Number: CRL-3272

Record Creation Time: 20220427T220803+0000

Ratings and Alerts

No rating or validation information has been found for MES-OV.

No alerts have been found for MES-OV.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Mortan LF, et al. (2026) Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer. Cells, 15(3).

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell, 189(10), 2898.

Evtimov VJ, et al. (2024) Targeting TAG-72 in cutaneous T cell lymphoma. Heliyon, 10(17), e36298.

Elayapillai S, et al. (2021) Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecologic oncology, 160(1), 302.

Ramraj SK, et al. (2020) Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. International journal of cancer, 147(4), 1086.